Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety

Seyed Alavian; Vahid Tabatabaee; Kamran Lankarani

Nephro-Urology Monthly

Current Issue All Issues In Press Search Accepted Manuscripts

Journal Information Boards and Committees Indexing and Listing Sources Publication Ethics and Malpractice Statement Support Reviewer and AE Registration Form Contact Us Journal Metrics Open Peer Review (OPR)

APC

Authors Guide Submit Manuscript

Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety

Author(s):

Seyed Moayed Alavian

^1,*,

Vahid Tabatabaee²,

Kamran Bagheri Lankarani³

1Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran Hepatitis Center, [email protected], Tehran, IR.Iran

2Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran Hepatitis Center, Tehran, IR.Iran

3Shiraz University of Medical Sciences, Fars, IR.Iran

Nephro-Urology Monthly:Vol. 3, issue 1; 1-7

Published online:Jan 31, 2011

Article type:Review Article

Received:Jun 06, 2010

Accepted:Jul 10, 2010

How to Cite:Alavian S, Tabatabaee V, Lankarani K. Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety. Nephro-Urol Mon. 2011;3(1):. doi:

Abstract

Background and Aims: Only few small studies have evaluated efficacy of ribavirin in combination with pegylated interferon or standard interferon in hemodialysis patients. In current review, we aim to determine the efficacy and safety of ribavirin-containing regimen in these patients.

Methods: Medline, Scopus, ISI web of knowledge and Proquest were searched for prospective studies of IFN and PEG-IFN combined with ribavirin in IFN-naive dialysis patients with chronic Hepatitis C infection. Reporting of HCV RNA results at least 6 months after treatment using a PCR assay was mandatory.

Results: From 17 relevant studies, six studies met our inclusion criteria. Because of high level of heterogeneity and low number of studies, we discarded meta-analysis. Two studies investigated standard interferon plus ribavirin. One reported 66% of Sustained Viral Response and zero treatment discontinuation. In contrast, another study reported just 16% of Sustained Viral Response and 33% of treatment discontinuation. Four studies investigated pegylated interferon plus ribavirin. One study reported amazing Sustained Viral Response rate of 97%, however, another study reported Sustained Viral Response rate of just 28.6% and treatment discontinuation rate of 71.4%. Other reported Sustained Viral Response and treatment discontinuation rates were 50%, 70% and 16%, respectively.

Conclusion: Individuals on dialysis with chronic hepatitis C who were treated with interferon or pegylated interferon plus ribavirin can have higher Sustained Viral Response rate than dialysis patients treated with interferon or pegylated interferon alone. Administration of ribavirin with close monitoring of CBC and serum ribavirin concentration can be safe.

Keywords

Ribavirin

End Stage Renal Disease

Dialysis

Interferon

Pegylated Interferon

Full Text

Full text is available in PDF

Conventional Interferon Alpha Therapy of Chronic Hepatitis C in Patients with End Stage Renal Disease, Six versus Twelve Months? A Meta-Analysis

Seyed Moayed Alavian,

Seyed Vahid Tabatabaei

Alavian S, Tabatabaei S. Conventional Interferon Alpha Therapy of Chronic Hepatitis C in Patients with End Stage Renal Disease, Six versus Twelve Months? A Meta-Analysis. Nephro-Urol Mon. 2009;1(1):. doi:

18

Apr

2021

The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection

Kasra Ghanaat,

Heidar Sharafi,

Seyed Moayed Alavian

Ghanaat K, Sharafi H, Alavian SM. The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection. Nephro-Urol Mon. 2021;13(2):e114049. doi: https://doi.org/10.5812/numonthly.114049

30

Sep

2004

Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian

Seyed Moayed Alavian,

Behzad Hajarizadeh,

Bashir Hajibeigi,

Taher Doroudi,

Amir Kambiz Hamadanizadeh,

Koroush Abar

Alavian S, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh A, et al. Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian. Hepat Mon. 2004;4(7):. doi:

1

Jan

2015

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Heidar Sharafi,

Seyed Moayed Alavian,

Maryam Keshvari

Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955

30

Sep

2004

Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C

Mohammad Reza Zali,

Hamid Mohaghegh Shalmani,

Mohsen Norouzinia,

Amir Hooshang MohammadAlizadeh,

Azita Nowroozi,

Negar Behrouz

Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 1 week ago
Scopus by Title: 2
Last Update: 1 week ago
Scopus by Title (Ref): 2
Last Update: 1 week ago
CrossRef: 0
Last Update: 4 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Seyed Alavian:[PubMed][Scholar]
Vahid Tabatabaee:[PubMed][Scholar]
Kamran Lankarani:[PubMed][Scholar]

Outlines

Ribavirin Combination Therapy of Chronic Hepatitis C Patients with End Stage Renal Disease: Review of Evidences on Efficacy and Safety

Abstract

Full Text

Similar Articles

Conventional Interferon Alpha Therapy of Chronic Hepatitis C in Patients with End Stage Renal Disease, Six versus Twelve Months? A Meta-Analysis

The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection

Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranian

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 4 days ago